Other

Other
2025-02-21T00:00:00.000+11:00
Ongoing

LAVA-1266

LAVA-1266
Leukaemia

A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2 T cell engager, in patients with relapsed/refractory acute myeloid leukemia and intermediate risk, high risk, or extremely high risk myelodysplastic syndrome.

A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2 T cell engager, in patients with relapsed/refractory acute myeloid leukemia and intermediate risk, high risk, or extremely high-risk myelodysplastic syndrome.

Trial overview

Clinical Area

Haematology

Disease

Leukaemia

Disease site

Malignant Haematology

Study Phase

I / II a

Trial Identifiers

Registration number: ACTRN12624001214527

https://www.anzctr.org.au/

GenesisCare Location(s)
St Andrew's Precinct (Oncology)
location pin icon

Level 1, 337 South Terrace, Adelaide, SA, 5000, Australia

phone icon (08) 8228 6700 email icon infooncologysa@genesiscare.com
SA
St Andrew's Precinct (Oncology)
Principal Investigator(s)
Haematologist

A/Prof Ian Lewis

MBBS PhD FRACP FRCPA

A/Prof Ian Lewis
location pin icon

Elizabeth Vale (Playford Health Hub) +2

View Profile
Profile Image - A/Prof Ian  Lewis

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.